MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma

Qi Liu, Qiyuan Bao, Yiqi Xu, Yucheng Fu, Zhijian Jin, Jun Wang, Weibin Zhang, Yuhui ShenFrontiers in Cell and Developmental Biology 2021 · DOI

Abstract

Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report, we comprehensively analyzed the expression profiles of 100 liposarcomas (LPSs), the most common STS subtype, in comparison with 21 adipose tissues from multiple GEO datasets to identify the potential prognostic and therapeutic biomarker for LPS. Furthermore, we investigated TCGA database, our archived tumor samples, and patient-derived tumor cell cultures (PTCCs) as a validation. We identified a total of 69 common differentially expressed genes (DEGs) among public datasets, with mini-chromosome maintenance protein 4 (MCM4) identified as a novel biomarker correlated with patients' clinical staging and survival outcome. MCM4-high expression LPS was characterized by MCM4 copy number increase, genomic instability, and BRCAness phenotype compared with the MCM4-low expression counterpart. In contrast, the mutational and the immune landscape were minimally different between the two groups. Interestingly, the association of MCM4-high expression with genomic instability and BRCAness were not only validated in LPS samples from our institution (n = 66) but also could be expanded to the pan-sarcoma cohort from TCGA database (n = 263). Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS.

Introduction

Soft-tissue sarcomas (STS) are a notoriously complex group of rare cancers, encompassing over 70 distinct histological subtypes. Currently, clinical management relies heavily on histology—the appearance of cells under a microscope—to predict tumor behavior and guide treatment. However, histology is often an unreliable predictor of therapeutic response. While therapies targeting DNA repair pathways (such as PARP inhibitors) have revolutionized treatment for cancers like breast and ovarian cancer, they have seen limited success in STS. This study addresses the urgent need for a molecular "compass": a biomarker capable of identifying tumors with underlying DNA repair defects, specifically the "BRCAness" phenotype, regardless of their histological classification.

Methods and Discovery

The researchers employed a multi-stage validation pipeline to identify and prioritize potential biomarkers. Initially, bioinformatics discovery involved analyzing three Gene Expression Omnibus (GEO) datasets (GSE21124, GSE51049, and GSE62747) to identify 69 common differentially expressed genes (DEGs) between liposarcoma—the most common STS—and normal adipose tissue.

Study workflow and identification of MCM4 as a key prognostic hub gene through multi-omics analysis.

Using protein-protein interaction (PPI) networks and Cox regression analysis on The Cancer Genome Atlas (TCGA) data, these 69 genes were narrowed down to four "hub" genes. Among these, MCM4 (mini-chromosome maintenance protein 4) emerged as the strongest independent risk factor for patient survival. The study further characterized MCM4-high and MCM4-low tumors across mutational landscapes, copy number variations (CNVs), and methylation patterns.

Key Insights: MCM4 as a Proxy for BRCAness

MCM4 is traditionally known as a DNA replication licensing factor. However, this research demonstrates that its overexpression serves as a hallmark of "BRCAness"—a state where a cell's ability to repair double-strand DNA breaks via homologous recombination is compromised, even in the absence of germline BRCA1/2 mutations.

Notably, MCM4-high tumors did not necessarily exhibit a higher overall tumor mutational burden (TMB). Instead, they showed significantly higher genomic instability, measured by the weighted Genome Instability Index (wGII). This distinguishes MCM4 as a marker of structural chromosomal chaos rather than simple point mutations. Furthermore, MCM4 expression was found to be highly specific to STS and testis tissue, suggesting it could be a "clean" therapeutic target with minimal expression in most healthy adult tissues.

Therapeutic Implications

The most striking finding of the study is the histology-agnostic nature of MCM4-linked vulnerability. High MCM4 expression predicted sensitivity to DNA-damaging agents across various sarcoma subtypes.

Validation of therapeutic sensitivity to PARP inhibitors and cisplatin in sarcoma cell lines and patient-derived cultures.

In functional testing using eight patient-derived tumor cell cultures (PTCCs) and four established sarcoma cell lines, the MCM4-high group demonstrated dramatically increased sensitivity to cisplatin and PARP inhibitors. For instance, MCM4-high PTCCs showed cisplatin IC50 values between 0.001–0.075 µM, compared to 0.403–0.827 µM in the MCM4-low group.

Conclusion

This study identifies MCM4 as a novel prognostic biomarker and a potential gatekeeper for precision medicine in soft-tissue sarcoma. By identifying the BRCAness phenotype, MCM4 can stratify patients who are likely to benefit from PARP inhibitors and platinum-based chemotherapies, moving the field toward molecularly-driven rather than histology-driven treatment strategies. While further prospective clinical trials are necessary to confirm these findings, MCM4 represents a promising step toward overcoming the therapeutic stagnation in STS management.

Summary updated

Abstract

Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report, we comprehensively analyzed the expression profiles of 100 liposarcomas (LPSs), the most common STS subtype, in comparison with 21 adipose tissues from multiple GEO datasets to identify the potential prognostic and therapeutic biomarker for LPS. Furthermore, we investigated TCGA database, our archived tumor samples, and patient-derived tumor cell cultures (PTCCs) as a validation. We identified a total of 69 common differentially expressed genes (DEGs) among public datasets, with mini-chromosome maintenance protein 4 (MCM4) identified as a novel biomarker correlated with patients' clinical staging and survival outcome. MCM4-high expression LPS was characterized by MCM4 copy number increase, genomic instability, and BRCAness phenotype compared with the MCM4-low expression counterpart. In contrast, the mutational and the immune landscape were minimally different between the two groups. Interestingly, the association of MCM4-high expression with genomic instability and BRCAness were not only validated in LPS samples from our institution (<i>n</i> = 66) but also could be expanded to the pan-sarcoma cohort from TCGA database (<i>n</i> = 263). Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS.
BibTeX
@inproceedings{liu2021mcm,
  author = {Qi Liu and Qiyuan Bao and Yiqi Xu and Yucheng Fu and Zhijian Jin and Jun Wang and Weibin Zhang and Yuhui Shen},
  title = {{MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.666376},
}
Figure